Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.70 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.54 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7280971 | 0.87 | PDE5A (0.67) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7280272 | 0.86 | PDE5A (0.52) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7440023 | 0.85 | PDE5A (0.68) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7441696 | 0.85 | PDE5A (0.58) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7373964 | 0.85 | PDE5A (0.69) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7433378 | 0.85 | PDE5A (0.57) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7277884 | 0.85 | PDE5A (0.57) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL688671 | 0.85 | PDE5A (0.74) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| Hydrochloric Acid SCHEMBL7437740 | 0.84 | PDE5A (0.57) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7428140 | 0.84 | PDE5A (0.56) | PDE5ATBXAS1PDE3BPDE3APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2241565-A1 | Aurora kinase inhibitors compounds | Universität Leipzig (DE) | 2010-10-20 | — | — | EP | claimed |
| US-20030203899-A1 | Drugs for incontinence | NICOX S.A. (FR) | 2003-10-30 | — | — | US | claimed |
| US-20030171393-A1 | Drugs for sex dysfunctions | NICOX S.A. (FR) | 2003-09-11 | — | — | US | claimed |
| US-5436233-A | Nervous system disorders | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-07-25 | — | — | US | claimed |
| EP-2241565-A1 | Aurora kinase inhibitors compounds | Universität Leipzig (DE) | 2010-10-20 | — | — | EP | disclosed |
| EP-2241565-A1 | Aurora kinase inhibitors compounds | Universität Leipzig (DE) | 2010-10-20 | — | — | EP | disclosed |
| WO-2010081881-A1 | AURORA KINASE INHIBITORS COMPOUNDS. | UNIVERSITÄT LEIPZIG (DE) | 2010-07-22 | — | — | WO | disclosed |
| EP-1363628-A2 | DRUGS FOR SEX DYSFUNCTIONS | NICOX S.A. (FR) | 2003-11-26 | — | — | EP | disclosed |
| US-20030203899-A1 | Drugs for incontinence | NICOX S.A. (FR) | 2003-10-30 | — | — | US | disclosed |
| US-20030171393-A1 | Drugs for sex dysfunctions | NICOX S.A. (FR) | 2003-09-11 | — | — | US | disclosed |
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | OSI PHARMACEUTICALS, INC. | 2002-02-28 | — | — | US | disclosed |
| WO-2002011706-A2 | DRUGS FOR SEX DYSFUNCTIONS | NICOX S.A. (FR) | 2002-02-14 | — | — | WO | disclosed |
| EP-0579496-B1 | 4-Aminoquinazoline derivatives, and their use as medicine | ONO PHARMACEUTICAL CO (JP) | 2001-11-14 | — | — | EP | disclosed |
| US-5439895-A | Cardiovascular disorders; inhibitor of thromboxane A2 synthetase and cyclic guanosine 3',5'-monophosphate | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-08-08 | — | — | US | disclosed |
| US-5436233-A | Nervous system disorders | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-07-25 | — | — | US | disclosed |
| EP-0579496-A1 | 4-Aminoquinazoline derivatives, and their use as medicine | ONO PHARMACEUTICAL CO., LTD. (JP) | 1994-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171393-A1 | Drugs for sex dysfunctions | SRD5A1, SRD5A2, XDH | PDE5A 18/4885TBXAS1 697/4885PDE3B 38/4885 |
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | VHL, MCL1, NFATC1 | PDE5A 3794/4885TBXAS1 977/4885PDE3B 3026/4885 |
| US-20030203899-A1 | Drugs for incontinence | PDE3A, NOS1, PDE3B | PDE5A 5/4885TBXAS1 585/4885PDE3B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.